Scientific illustration of a senescent cell, inflammatory signalling, immune clearance and calmer tissue
Geroprotect Blog

Geroprotect research note · Evidence review

Clear, Quiet, Spare

Fisetin, quercetin and apigenin—three proposed jobs, and the CD38 link to NAD+

Abstract

My working model is easy to remember: clear, quiet, spare. Fisetin is a proposed natural senolytic—a candidate for clearing some senescent cells in some preclinical settings. Quercetin may affect senescent-cell survival and inflammatory signalling, although my description of it as “senomorphic” at ordinary oral exposure remains an interpretation, not an established human action. Apigenin and quercetin inhibit the NAD+-consuming enzyme CD38 in purified-enzyme and cell experiments, while apigenin has raised tissue NAD+ in mouse studies. That makes CD38 an attractive mechanistic bridge between senescence and NAD+ metabolism.

The evidence does not yet validate this architecture as a human longevity intervention. Fisetin improved physical function in an intermittent mouse experiment, but the rigorously replicated NIA Interventions Testing Program found no lifespan extension with either continuous or cyclic dietary fisetin. Human data are not absent: standalone quercetin and fisetin trials have measured cardiovascular, metabolic, inflammatory and disease-specific outcomes, and dasatinib-plus-quercetin has entered early senolytic trials. Those records do not show that either flavonoid alone reliably clears senescent cells in people or that the Geroprotect formula improves aging. CD38 results are mainly from cells, mice and rats; no human trial has shown that apigenin or quercetin makes an NAD+ precursor clinically more effective. This note keeps the mechanistic thesis, but grades each claim by the experiment that actually supports it.

1. Senescence: useful state, harmful accumulation

A damaged cell does not always repair itself or die. It can enter a durable growth arrest called cellular senescence. That response is not intrinsically bad. Senescence contributes to tumour suppression, development, wound repair and tissue remodelling. The difficulty comes when senescent cells persist, resist apoptosis and release a changing mixture of cytokines, chemokines, growth factors and proteases known collectively as the senescence-associated secretory phenotype, or SASP.

In ageing animals, persistent senescent cells can disturb neighbouring cells, reshape immune activity and degrade tissue function. Genetic systems that remove selected p16Ink4a-expressing cells have delayed several age-related phenotypes and extended median lifespan in mice.1 Those experiments are powerful causal evidence in those models. They do not mean every p16-positive cell is harmful, every senescent cell is equivalent, or every chemical labelled “senolytic” will reproduce genetic clearance in people.

That distinction matters. Senescence is heterogeneous across cell types, tissues and triggers. A compound that selectively kills a radiation-induced senescent endothelial cell in a dish may not kill a senescent adipocyte, immune cell or neuron in a living human. Even the early dasatinib-plus-quercetin work showed cell-type specificity: dasatinib was more effective against senescent human preadipocytes, while quercetin was more effective against senescent endothelial cells and mouse bone-marrow mesenchymal stem cells.2

So the biology is strong, but I no longer call the pharmacology settled. The honest chain is longer: identify a senescent population, show selective target engagement, show that changing that population alters a meaningful outcome, and then reproduce the result in an adequately controlled human study.

2. Fisetin: a positive function study and a rigorous lifespan null

Fisetin became prominent after cell and animal work suggested that it could reduce selected senescent-cell markers and improve late-life outcomes. A 2018 study reported effects in progeroid and naturally aged mice, including a small lifespan experiment.3 Useful as that work was, the lifespan arm was small and could not substitute for a large, replicated longevity study.

The result that must lead the discussion

The NIA Interventions Testing Program is designed to reduce the chance that a result depends on one laboratory. It tests genetically heterogeneous UM-HET3 mice at three sites. In its fisetin experiment, treatment began at 20 months of age. The target concentration was 600 ppm in food, and measured diet content averaged 99% of target, with a reported standard error of 9%. One group received fisetin continuously. Another received it for three days followed by eleven days without fisetin, repeated every two weeks.4

Neither schedule significantly extended lifespan in either sex. In pooled males, the cyclic group had a seven-percent higher median than controls, but the survival comparison was not significant; the continuous group had a lower median. Female results were also null. The investigators could not measure plasma fisetin reliably, and fisetin did not significantly lower whole-tissue p16Ink4a messenger RNA in the sampled liver, kidney or brain. Those limitations prevent a clean conclusion about pharmacokinetic exposure or successful senescent-cell clearance. They do not erase the outcome: at the doses, route and schedules tested, fisetin did not extend lifespan.

This corrects an important shorthand in the source note. The ITP result cannot be dismissed as “continuous dosing only.” It included a cyclic dietary schedule. It still did not test a short high-concentration gavage regimen, and its central endpoint was survival rather than a complete battery of functional outcomes. Both statements can be true without moving the goalposts.

What the 2025 mouse study adds

Murray and colleagues asked a different question in old mice. Their oral intermittent schedule was one week on, two weeks off, then one week on. Fisetin mitigated age-associated frailty and grip-strength deficits and produced favourable changes in the skeletal-muscle transcriptome, including lower abundance of the senescence-related genes Cdkn1a and Ddit4. The functional improvements were comparable in magnitude to those seen with genetic p16-positive-cell clearance and with intermittent navitoclax (ABT-263) in the study’s comparison experiments.5

That is meaningful preclinical evidence for physical function. It is not evidence that fisetin extends human life, prevents frailty in people or is the “strongest natural senolytic.” Cross-study rankings of that kind are not defensible when models, tissues, formulations and endpoints differ.

What the published and posted human record contains

Fisetin is not “animal data only.” A double-blind randomized trial gave 100 mg/day to 37 people with colorectal cancer receiving chemotherapy for seven weeks. IL-8 changed significantly versus placebo; the between-group results for the other measured inflammatory and matrix-remodelling markers were not significant.23 A separate 192-person randomized trial studied 100 mg/day for seven days alongside rt-PA after acute ischemic stroke and reported neurological and biomarker findings; no prospective trial-registration identifier was identified in that paper.24 Both studies establish human intervention experience. Neither tested senescent-cell clearance, healthy aging or longevity, and neither used the current Geroprotect formula.

The most direct published human senescence-marker signal is smaller and less controlled. Hambright and colleagues followed ten self-selected participants who reported taking 100 mg/day. C12FDG-bright peripheral-blood mononuclear cells and several serum markers fell from baseline after an average of 58 days, but there was no randomized comparison group and the marker’s clinical meaning remains under study.25 This is exploratory target-engagement evidence, not a clinical-outcome verdict.

A completed knee-osteoarthritis trial provides an important controlled counterweight. The ClinicalTrials.gov record reports 74 randomized participants and intermittent dosing at approximately 20 mg/kg/day for two consecutive days, repeated after 28 days.26 The investigator conference report found no significant between-group benefit for pain, physical function, strength, gait or cartilage MRI and no difference in adverse-event measures.27 These are posted registry and conference results rather than a full peer-reviewed results paper, so both the null outcome and the reporting stage should remain visible.

A ten-person uncontrolled pilot used 500 mg/day for one week per month over six months and reported mixed methylation-age movement: four participants decreased, five increased and one did not change.28 Without a control group, that study cannot distinguish treatment from measurement variation, time or regression to the mean.

As of 14 July 2026, the two Mayo Clinic fisetin studies most often cited here—AFFIRM in older women (NCT03430037) and AFFIRM-LITE in older adults (NCT03675724)—are listed as enrolling by invitation, with no results posted on ClinicalTrials.gov.1516 The separate ROPE knee-osteoarthritis study (NCT04770064) was withdrawn before enrolment.17 Trial records can change, which is why status claims are dated.

My conclusion is deliberately narrow: fisetin has real human intervention data and remains an actively studied senotherapeutic candidate. Human senolytic efficacy, broad healthy-aging benefit and the effect of the 300 mg amount in Essentials I remain unresolved. This note does not supply or endorse a pulsed self-dosing protocol.

3. Quercetin: senolytic evidence, senomorphic hypothesis

Quercetin is difficult to assign one verb because it engages many targets and behaves differently across models. In the foundational 2015 work, quercetin selectively reduced viability of certain senescent cell types in culture and contributed to the effects of dasatinib plus quercetin in mice.2 That supports a senolytic classification in defined experimental settings. It does not establish that quercetin alone, at an oral supplement dose, clears senescent cells in humans.

I have used “quiet” as a shorthand for a possible senomorphic role: reducing inflammatory output or modifying the SASP without necessarily clearing the cell. The idea is biologically plausible, and cell studies report effects on inflammatory signalling. But oral bioavailability is variable, circulating metabolites differ from the parent compound used in many studies, and no controlled human study has shown that ordinary quercetin supplementation suppresses a senescent-cell SASP in vivo while leaving cell abundance unchanged. “Senomorphic at achievable oral doses” should therefore be read as my mechanistic hypothesis, not as a clinically established mechanism.

Quercetin itself has randomized human trials—just not proof of human senolysis

Standalone quercetin has a materially larger human record than an animal-only badge suggests. In 93 adults with overweight or obesity and metabolic-syndrome traits, 150 mg/day for six weeks reduced systolic blood pressure by 2.6 mmHg versus placebo, while lipid results were mixed.19 In a 22-person crossover trial, 500 mg/day for four weeks lowered plasma uric acid by 26.5 μmol/L but did not change fasting glucose, urinary uric-acid excretion or resting blood pressure.20 Conversely, an 88-person post-myocardial-infarction trial found no significant effect of 500 mg/day for eight weeks on ICAM-1, VCAM-1 or depression versus placebo.21

A 2025 phase 1 programme also reported dose-finding, pharmacokinetic and tolerability data in children and young adults with Fanconi anaemia.22 That is useful human clinical knowledge in a specific rare-disease population, not a senolytic or healthy-aging efficacy result. Together, these studies justify “Human RCT” and “Human clinical” study-type labels for quercetin. They do not establish that the 300 mg amount in Essentials I reproduces any one result, clears senescent cells or improves longevity.

What the dasatinib-plus-quercetin trials actually found

The clearest randomized evidence comes from a phase 2 study in 60 postmenopausal women. Intermittent dasatinib plus quercetin did not improve the primary endpoint, the 20-week change in the bone-resorption marker C-terminal telopeptide, compared with control. In exploratory analyses, women in the highest tertile of baseline T-cell p16 messenger RNA had nominal improvements in bone-turnover markers and radius bone mineral density.6 That is an intriguing burden-response hypothesis. Because it comes from exploratory subgroup analyses across multiple outcomes, it needs prospective confirmation in a trial designed and powered around a pre-specified burden marker.

STAMINA was a 12-person, single-arm feasibility study in older adults with slow gait and mild cognitive impairment. Participants received dasatinib plus quercetin for two days every two weeks over 12 weeks. There were no intervention-related serious adverse events. The mean Montreal Cognitive Assessment change for the full group was one point and not statistically significant. A subgroup with the lowest baseline scores improved by a mean two points, with a confidence interval just above zero.7 With no placebo group, a tiny sample and subgrouping by baseline performance, practice effects, chance and regression to the mean cannot be separated from treatment. The investigators themselves describe the efficacy findings as hypothesis-generating.

SToMP-AD enrolled five people with mild Alzheimer’s disease in an open-label phase 1 study. Its primary goal was central-nervous-system penetration, not clinical efficacy. Dasatinib was detectable in cerebrospinal fluid in four participants; quercetin was not detected there. Cognitive and neuroimaging measures did not significantly change, and the biomarker findings were exploratory.8

These are combination studies involving dasatinib, a prescription kinase inhibitor. They cannot tell us what quercetin alone does. Nor do they establish a repeated rule that “the most damaged people respond.” They suggest a testable possibility: future senolytic trials may need validated enrichment markers for senescent-cell burden and prospectively defined responder analyses.

4. Apigenin, CD38 and the NAD+ link

Nicotinamide adenine dinucleotide, or NAD+, participates in redox metabolism and serves as a substrate for several enzyme families, including sirtuins, PARPs and CD38. NAD+ concentrations decline with age in many—but not all—tissues and experimental contexts. It is too simple to say that one enzyme explains the entire decline. CD38 is nevertheless an important age-associated NADase in mouse work.

Camacho-Pereira and colleagues found that CD38 expression and activity rose with age in mice. CD38 deficiency protected against age-related NAD+ decline and mitochondrial dysfunction through a pathway involving SIRT3, and CD38 also degraded the NAD+ precursor NMN in vivo.9 Later work linked senescence-associated inflammation to the accumulation of CD38-positive immune cells. That gives the “clear” and “spare” sides of the model a plausible biological connection, but the evidence is still predominantly preclinical.

What apigenin and quercetin did in the CD38 experiments

Escande and colleagues screened flavonoids against purified human CD38. Apigenin inhibited its NADase activity with a half-maximal inhibitory concentration of about 10.3 micromolar; quercetin’s was about 13.8 micromolar. Both altered intracellular NAD+ in cell experiments. In high-fat-fed mice, daily intraperitoneal apigenin at 100 mg per kilogram for one week reduced liver CD38 activity, increased hepatic NAD+ and reduced protein acetylation; several metabolic measures also improved.10

Those are strong mechanistic observations, but the route and exposure matter. An injected mouse experiment at 100 mg per kilogram is not evidence that a human oral supplement reaches the same tissue concentration or produces the same effect. The paper supports “apigenin can inhibit CD38 in these systems,” not “apigenin has clinically spared NAD+ in people.”

In diabetic rats, apigenin reduced renal CD38 expression and restored the NAD+/NADH ratio and SIRT3-associated antioxidant activity while improving kidney injury markers.11 Again, that is a disease-model result in rodents, not proof of a human longevity benefit.

CD38 is not the whole apigenin story

A 2025 study in human monocytes and macrophages found that apigenin reduced NLRP3 inflammasome activation, but the effect persisted in CD38-deficient mouse macrophages. The authors concluded that apigenin’s NLRP3 effect was independent of CD38 in their models.12 This is useful discipline: a compound can produce two effects without one causing the other.

The attractive formulation logic is to supply an NAD+ precursor while reducing NAD+ consumption. But no human randomized trial has shown that apigenin or quercetin inhibits CD38 in the relevant tissues, raises tissue NAD+ through that mechanism, or makes NMN or NR produce a better clinical outcome. “Patch the leak while filling the tank” is a memorable hypothesis. It is not yet a demonstrated human intervention.

5. Pterostilbene: target engagement is not recovery

Pterostilbene sits slightly outside the clear–quiet–spare triad, but it is useful because it shows why biomarkers and outcomes must not be confused. In a randomized, placebo-controlled study, 32 adults aged 55 to 80 received 1,000 mg nicotinamide riboside plus 200 mg pterostilbene daily or placebo around an experimentally induced muscle injury. The intervention changed blood NAD+ metabolism, showing biological exposure, but did not improve muscle-stem-cell recruitment, strength recovery or the other measured indices of muscle regeneration.13

That is a high-value null. The pathway moved; the clinical model did not improve. It is a warning against treating a rise in NAD+ as a surrogate for every outcome we care about.

A 2026 open-label pilot gave 40 women 250 mg NR plus 50 mg pterostilbene daily for seven days; 32 reported menopause-transition symptoms at baseline. Symptom scores and the urinary estradiol-to-estrone ratio changed after treatment.14 With no placebo group, a one-week duration, self-reported symptoms and no clinical staging requirement for the menopause transition, the study cannot establish efficacy. It is a rationale for a blinded randomized trial, not a result on which I would base a health claim.

6. Clear, quiet, spare—properly qualified

I still find the three-verb architecture useful, provided the verbs carry their evidence labels. It prevents chemically similar-looking ingredients from being treated as interchangeable “antioxidants,” while making uncertainty visible.

Working roles and their present evidence limits
Working verbCompoundWhat supports itWhat is not established
ClearFisetinSelective senolytic activity in some cell models; intermittent dosing improved physical function and senescence-related transcripts in old mice.Reliable senescent-cell clearance, functional benefit, disease prevention or longevity extension in humans.
QuietQuercetinCell-type-specific senolytic activity, broad signalling effects and exploratory human data as part of dasatinib-plus-quercetin.A senomorphic action at ordinary oral exposure, or efficacy of quercetin alone, in humans.
SpareApigenin and quercetinInhibition of purified CD38; cellular and rodent NAD+ effects, especially for apigenin.Clinically meaningful CD38 inhibition or potentiation of an NAD+ precursor in humans.

This framework is a formulation rationale, not product validation. Geroprotect may use mechanistic complementarity when selecting ingredients, but combining plausible mechanisms does not multiply them into proven efficacy. Absorption, metabolism, tissue exposure, interactions and dose all sit between an elegant pathway diagram and a human outcome.

7. What the human evidence can and cannot say

The human senolytic literature remains thin even though both fisetin and quercetin have been studied in people for other questions. Biomarkers of senescent-cell burden remain imperfect, target tissues are hard to sample and ageing itself is not a single short-duration endpoint. Funding incentives for unpatentable natural compounds may also matter, but they are not the only explanation. Small studies are not automatically positive studies waiting to be enlarged; they are often designed for safety, feasibility or pharmacokinetics and cannot answer efficacy questions.

I grade the evidence in five steps:

  1. Mechanism: does a compound bind or inhibit the proposed target in a purified system?
  2. Cell context: does it act selectively in relevant senescent and non-senescent human cell types?
  3. Animal target engagement: does the intended tissue change at a measured exposure?
  4. Human target engagement: is the mechanism demonstrated in people, not inferred from the ingredient list?
  5. Human outcome: does a randomized, adequately powered trial improve a pre-specified clinical endpoint?

Fisetin has reached human intervention studies, including randomized disease-specific trials, but its direct human senescence-marker evidence remains an uncontrolled ten-person signal and controlled clinical outcomes are mixed or null across contexts. Quercetin has multiple standalone randomized trials for non-senolytic endpoints, a phase 1 programme and early combination-trial data with dasatinib that cannot isolate its contribution. Apigenin’s CD38 case is strong at steps one through three, but not yet four or five. The D+Q bone subgroup and low-baseline-cognition STAMINA subgroup are useful for designing future studies; neither clears the threshold for a clinical recommendation.

My position, stated plainly, is this: persistent cellular senescence is an important causal driver in multiple animal models. Natural senotherapeutics are promising but unproven as human longevity treatments. CD38 is a persuasive preclinical link between inflammation and NAD+ loss, not yet a validated reason to expect a flavonoid–NAD-precursor combination to improve human outcomes. Reporting the nulls is not pessimism. It is how the hypothesis becomes testable.

Frequently asked questions

Is fisetin a proven senolytic in humans?

No. Human fisetin trials do exist, including randomized studies in disease-specific settings. The direct senescence-marker signal is a small uncontrolled longitudinal subgroup, while a completed randomized knee-osteoarthritis study reported no benefit for its tested clinical and imaging outcomes. The record does not establish that oral fisetin reliably clears senescent cells or improves broad healthy-aging outcomes.

Did the Interventions Testing Program use only continuous fisetin?

No. It tested continuous dietary fisetin and a cycle of three days on followed by eleven days off, beginning at 20 months of age. Neither schedule significantly extended lifespan. The study did not establish reliable plasma exposure or a reduction in its sampled whole-tissue p16 messenger RNA, so it is a null for the tested interventions—not proof that every conceivable fisetin exposure must fail.

Is quercetin a senolytic or a senomorphic?

It depends on what has actually been measured. Quercetin has shown senolytic activity in selected cultured cells and has multiple human randomized trials for other, endpoint-specific questions. The proposal that oral quercetin acts mainly as a senomorphic—or clears senescent cells—in people has not been demonstrated in a controlled standalone human study. A label should not outrun the experiment.

Did dasatinib plus quercetin improve cognition?

That has not been established. In the 12-person, uncontrolled STAMINA pilot, the full-group MoCA change was not statistically significant. A lower-baseline subgroup improved, but that exploratory result is vulnerable to chance and regression to the mean. SToMP-AD was a five-person phase 1 penetration and feasibility study, not an efficacy trial.

Does apigenin increase NAD+ in humans?

There is no good clinical evidence showing that oral apigenin raises tissue NAD+ in humans through CD38 inhibition. The strongest evidence comes from purified enzyme assays, cells and rodent studies.

Should fisetin, quercetin and apigenin be taken together or in pulses?

This review does not recommend a dosing protocol. No human trial has established that this three-compound combination improves healthspan, and a prescription medicine such as dasatinib must never be folded into a self-directed “senolytic” regimen. Individual risks, interactions and product quality require clinical review.

How to cite

van Dieten WT. Clear, Quiet, Spare: fisetin, quercetin and apigenin—three flavonoids, three proposed jobs, and the CD38 link to NAD+. Geroprotect Blog. Source note 24 February 2026; reviewed web edition 14 July 2026.

References

  1. Baker DJ, Childs BG, Durik M, et al. Naturally occurring p16Ink4a-positive cells shorten healthy lifespan. Nature. 2016;530:184–189. doi:10.1038/nature16932.
  2. Zhu Y, Tchkonia T, Pirtskhalava T, et al. The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell. 2015;14(4):644–658. doi:10.1111/acel.12344.
  3. Yousefzadeh MJ, Zhu Y, McGowan SJ, et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine. 2018;36:18–28. doi:10.1016/j.ebiom.2018.09.015.
  4. Harrison DE, Strong R, Reifsnyder P, et al. Astaxanthin and meclizine extend lifespan in UM-HET3 male mice; fisetin, SG1002, dimethyl fumarate, mycophenolic acid, and 4-phenylbutyrate do not significantly affect lifespan in either sex at the doses and schedules used. GeroScience. 2024;46:795–816. doi:10.1007/s11357-023-01011-0.
  5. Murray KO, Mahoney SA, Ludwig KR, et al. Intermittent supplementation with fisetin improves physical function and decreases cellular senescence in skeletal muscle with aging. Aging Cell. 2025;24(8):e70114. doi:10.1111/acel.70114.
  6. Farr JN, et al. Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial. Nature Medicine. 2024;30(9):2605–2612. doi:10.1038/s41591-024-03096-2.
  7. Millar CL, Iloputaife I, Baldyga K, et al. A pilot study of senolytics to improve cognition and mobility in older adults at risk for Alzheimer’s disease. EBioMedicine. 2025;113:105612. doi:10.1016/j.ebiom.2025.105612. Trial: NCT05422885.
  8. Gonzales MM, Garbarino VR, Kautz T, et al. Senolytic therapy in mild Alzheimer’s disease: a phase 1 feasibility trial. Nature Medicine. 2023;29(10):2481–2488. doi:10.1038/s41591-023-02543-w. Trial: NCT04063124.
  9. Camacho-Pereira J, Tarragó MG, Chini CCS, et al. CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism. Cell Metabolism. 2016;23(6):1127–1139. doi:10.1016/j.cmet.2016.05.006.
  10. Escande C, Nin V, Price NL, et al. Flavonoid apigenin is an inhibitor of the NAD+ase CD38: implications for cellular NAD+ metabolism, protein acetylation, and treatment of metabolic syndrome. Diabetes. 2013;62(4):1084–1093. doi:10.2337/db12-1139.
  11. Ogura Y, Kitada M, Xu J, Monno I, Koya D. CD38 inhibition by apigenin ameliorates mitochondrial oxidative stress through restoration of the intracellular NAD+/NADH ratio and Sirt3 activity in renal tubular cells in diabetic rats. Aging. 2020;12(12):11325–11336. doi:10.18632/aging.103410.
  12. Lauritzen KH, Yang K, Frisk M, et al. Apigenin inhibits NLRP3 inflammasome activation in monocytes and macrophages independently of CD38. Frontiers in Immunology. 2025;15:1497984. doi:10.3389/fimmu.2024.1497984.
  13. Jensen JB, Dollerup OL, Møller AB, et al. A randomized placebo-controlled trial of nicotinamide riboside and pterostilbene supplementation in experimental muscle injury in elderly individuals. JCI Insight. 2022;7(19):e158314. doi:10.1172/jci.insight.158314. Trial: NCT03754842.
  14. Holmes HE, Srivastava K, Scalici JM, et al. Nicotinamide riboside and pterostilbene reduces frequency and severity of undesirable symptoms of the menopause transition: an open-label, pilot clinical trial. Frontiers in Aging. 2026;7:1773667. doi:10.3389/fragi.2026.1773667. Trial: NCT04841499.
  15. ClinicalTrials.gov. Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Women (AFFIRM). NCT03430037. Record checked 14 July 2026.
  16. ClinicalTrials.gov. Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Adults (AFFIRM-LITE). NCT03675724. Record checked 14 July 2026.
  17. ClinicalTrials.gov. Targeting Senescence to Reduce Osteoarthritis Pain and cartilagE Breakdown (ROPE). NCT04770064. Record checked 14 July 2026.
  18. U.S. National Library of Medicine. Dasatinib tablets: full prescribing information. DailyMed. Revised February 2026. Official drug label.
  19. Egert S, Bosy-Westphal A, Seiberl J, et al. Quercetin reduces systolic blood pressure and plasma oxidised low-density lipoprotein concentrations in overweight subjects with a high-cardiovascular-disease-risk phenotype: a double-blinded, placebo-controlled cross-over study. British Journal of Nutrition. 2009;102(7):1065–1074. doi:10.1017/S0007114509359127. PMID 19402938.
  20. Shi Y, Williamson G. Quercetin lowers plasma uric acid in pre-hyperuricaemic males: a randomised, double-blinded, placebo-controlled, cross-over trial. British Journal of Nutrition. 2016;115(5):800–806. doi:10.1017/S0007114515005310. PMID 26785820.
  21. Dehghani F, Vafa M, Ebrahimkhani A, Găman MA, Sezavar Seyedi Jandaghi SH. Effects of quercetin supplementation on endothelial dysfunction biomarkers and depression in post-myocardial-infarction patients: a double-blind, placebo-controlled, randomized clinical trial. Clinical Nutrition ESPEN. 2023;56:73–80. doi:10.1016/j.clnesp.2023.04.019. PMID 37344086.
  22. Mehta PA, Nelson A, Loveless S, et al. Phase 1 study of quercetin, a natural antioxidant for children and young adults with Fanconi anemia. Blood Advances. 2025;9(8):1927–1939. doi:10.1182/bloodadvances.2024015053. PMID 39820512.
  23. Farsad-Naeimi A, Alizadeh M, Esfahani A, Darvish Aminabad E. Effect of fisetin supplementation on inflammatory factors and matrix metalloproteinase enzymes in colorectal cancer patients. Food & Function. 2018;9(4):2025–2031. doi:10.1039/C7FO01898C. PMID 29541713.
  24. Wang L, Cao D, Wu H, Jia H, Yang C, Zhang L. Fisetin prolongs therapy window of brain ischemic stroke using tissue plasminogen activator: a double-blind randomized placebo-controlled clinical trial. Clinical and Applied Thrombosis/Hemostasis. 2019;25:1076029619871359. doi:10.1177/1076029619871359. PMID 31434498.
  25. Hambright WS, Duke VR, Goff AD, et al. Clinical validation of C12FDG as a marker associated with senescence and osteoarthritic phenotypes. Aging Cell. 2024;23(5):e14113. doi:10.1111/acel.14113. PMID 38708778.
  26. ClinicalTrials.gov. Senolytic Drugs Attenuate Osteoarthritis-Related Articular Cartilage Degeneration: A Clinical Trial. NCT04210986 results. Record checked 14 July 2026.
  27. Tashman S, Evans T, Carcia A, et al. Results from a randomized clinical trial evaluating the senolytic fisetin for treating knee osteoarthritis. Orthopaedic Research Society 2025 Annual Meeting. Paper 429. Investigator conference report.
  28. Lee E, Burns M. The effects of fisetin on reducing biological aging: a pilot study. Alternative Therapies in Health and Medicine. 2024;30(9):6–10. PubMed record. PMID 39269340.

Quality you can check

Every badge links to the document behind it: manufacturer certificates, certificates of analysis for all 26 actives, and our own promises about the formula.

Huazhen Biotechnology (Shenzhen) holds ISO 22000:2018 certificate 015FSMS2400550 and HACCP certificate 015HACCP2400460, both valid until 2 December 2027. These are manufacturer system papers, not a product certificate. The earlier papers 150FSMS2200001 and 150HACCP2200001 ended in March 2025 and are not shown as valid. Halal certificates cover raw materials from our suppliers; Geroprotect Essentials is not registered as a halal product. Food supplement. Read the current product label before use.

Bought from Geroprotect? Leave an honest review:Review us on TrustpilotReview us on GoogleReview on Amazon.aeReviews are optional and never rewarded. More about reviews.
Scroll to Top